2024-2025年德国季节性流感疫苗有效性的中期估计——来自初级保健和医院哨点监测的数据

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2025-05-06 DOI:10.1111/irv.70115

Annika Erdwiens, Carolin Hackmann, Marianne Wedde, Barbara Biere, Janine Reiche, Ute Preuß, Kristin Tolksdorf, Silke Buda, Ralf Dürrwald

{"title":"2024-2025年德国季节性流感疫苗有效性的中期估计——来自初级保健和医院哨点监测的数据","authors":"Annika Erdwiens, Carolin Hackmann, Marianne Wedde, Barbara Biere, Janine Reiche, Ute Preuß, Kristin Tolksdorf, Silke Buda, Ralf Dürrwald","doi":"10.1111/irv.70115","DOIUrl":null,"url":null,"abstract":"<p>Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1–52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21–88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70115","citationCount":"0","resultStr":"{\"title\":\"Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance\",\"authors\":\"Annika Erdwiens, Carolin Hackmann, Marianne Wedde, Barbara Biere, Janine Reiche, Ute Preuß, Kristin Tolksdorf, Silke Buda, Ralf Dürrwald\",\"doi\":\"10.1111/irv.70115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1–52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21–88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.</p>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"19 5\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70115\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.70115\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70115","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

在2024年10月至2025年2月期间，甲型H1N1流感pdm09最初在德国占主导地位，随后B型流感/维多利亚共同流行。我们提供了2014 /2025年德国初级保健和二级保健流感疫苗有效性（VE）的中期估计。初级保健对任何流感的VE为31% （95% CI: 1-52）。中期VE对乙型流感呈高水平；然而，中期估计表明，特别是在60岁以下的成人年龄组中，对甲型流感的VE要低得多。在二级保健中，对任何流感的VE为69% （95% CI: 21-88）。我们的研究结果支持在预防感染行为和及时抗病毒治疗的同时促进流感疫苗接种。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance

查看原文本刊更多论文

Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance

Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co-circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1–52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21–88). Our findings support promoting influenza vaccination alongside infection-preventing behavior and prompt antiviral therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.